人脑胶质瘤组织中ERCC1、ARL2表达水平与患者病理特征、预后的关系  

Relationship between the expression levels of ERCC1 and ARL2 in human brain glioma and the pathological features and prognosis of patients

作　　者：陈恒三 郭超 王虎 魏祎 金明 于向阳 黄铭 周东春[1] 尚银武 路安庆[1] CHEN Hengsan;GUO Chao;WANG Hu;WEI Yi;JIN Ming;YU Xiangyang;HUANG Ming;ZHOU Dongchun;SHANG Yinwu;LU Anqing(Department of Neurosurgery,Gansu Provincial People's Hospital,Lanzhou,Gansu 730000,China)

机构地区：[1]甘肃省人民医院神经外科,甘肃兰州730000

出　　处：《中华神经外科疾病研究杂志》2025年第2期45-49,共5页Chinese Journal of Neurosurgical Disease Research

基　　金：甘肃省卫生健康行业科研计划项目(GSWSKY2022-83)。

摘　　要：目的探讨人脑胶质瘤(BG)组织中核苷酸切除修复交叉互补基因1(ERCC1)、ADP核糖基化样因子2(ARL2)表达水平与患者病理特征、预后的关系。方法选取2019年8月至2022年8月期间甘肃省人民医院收治的122例BG患者,将手术过程中取得的BG肿瘤组织标本纳入BG组(n=122),将同期因颅脑外伤而获取的正常脑组织标本纳入对照组(n=60)。采用免疫组化法检测ERCC1、ARL2在脑组织中的表达情况;通过χ2检验分析ERCC1、ARL2表达与BG临床病理特征的关系;采用多因素Cox回归分析探讨BG患者预后的影响因素。结果BG组ERCC1、ARL2的阳性表达率为69.67%、66.39%,高于对照组的28.33%、25.00%(P<0.05)。低分化BG患者的ERCC1阳性表达率、ARL2阳性表达率高于中/高分化患者(P<0.05)。122例BG患者出院后连续随访2年,59例存活,总生存率为48.36%(59/122)。中/高分化、ERCC1阴性、ARL2阴性患者的2年总生存率分别高于低分化、ERCC1阳性、ARL2阳性患者(P均<0.05)。低分化(HR=2.368,95%CI:1.442~3.888)、ERCC1阳性(HR=2.824,95%CI:1.634~4.879)、ARL2阳性(HR=3.370,95%CI:1.902~5.973)是BG患者预后的独立危险因素(P<0.05)。结论ERCC1、ARL2在BG患者脑组织中呈高表达,分化程度越低其表达水平越高,且ERCC1、ARL2与患者术后生存期有一定关联性。Objective To explore the relationship between the excision repair crosscomplementation group 1(ERCC1)and ADP ribosylated factor 2(ARL2)in human glioma(BG)tissues and the pathological characteristics and prognosis of patients.Methods 122 BG cases from August 2019 to August 2022 were selected.BG tumor tissue specimens obtained during surgery were included in the BG group(n=122),and normal brain tissue specimens obtained due to craniocerebral trauma during the same period were included in the control group(n=60).The expression of ERCC1 and ARL2 in brain tissue was detected by immunohistochemical method.The correlation between the ERCC1,ARL2 and the pathological features of BG was analyzed byχ2 test.The prognostic factors of human brain glioma patients were explored by Multivariate Cox regression analysis.Results The positive expression rates of ERCC1 and ARL2 in BG group were 69.67%and 66.39%,which were more than the respective figures of 28.33%and 25.00%in the control group(P<0.05).The positive expression rates of ERCC1 and ARL2 in poorly differentiated BG patients were higher than those in moderately differentiated/highly differentiated BG patients(P<0.05).These 122 BG patients were followed up for 2 years after discharge,and 59 of them survived,with an overall survival rate of 48.36%(59/122).The 2-year overall survival rate of patients with medium/high differentiation,ERCC1 negative and ARL2 negative was higher than that of patients with low differentiation,ERCC1 positive and ARL2 positive respectively(P<0.05).Low differentiation(HR=2.368,95%CI:1.442-3.888),positive ERCC1(HR=2.824,95%CI:1.634-4.879),positive ARL2(HR=3.370,95%CI:1.902-5.973)were independent risk factors for prognosis of human brain glioma patients(P<0.05).Conclusions ERCC1 and ARL2 are highly expressed in BG tissues,and their expression increases as the degree of differentiation decreases.ERCC1 and ARL2 are also associated with postoperative survival in patients.

关 键 词：人脑胶质瘤 核苷酸切除修复交叉互补基因1 ADP核糖基化样因子2 预后 

分 类 号：R739.41[医药卫生—肿瘤]